In muscle samples from dysferlinopathy patients, both AHNAK and dysferlin levels are reduced, with AHNAK showing a notable decrease in the sarcolemma but remaining stable in blood vessels, indicating a muscle-specific reduction. Here, DYSF is linked to neuromuscular disease caused by qualitative or quantitative defects of dysferlin.